Skip to content
Screener

Fortrea Holdings Inc. FTRE Clinical Services Segment — Revenue

Similar metrics at other companies

Neuronetics logo
STIMClinical Services — Revenue
$21.53M+15.4%
Maximus logo
MMSClinical Services — Revenue
$553.08M-1.3%
SRT
SRTAClinical — Revenue
$19.79M
WW International, Inc. logo
WWClinical Subscription Revenues — Revenue
$39.91M+38.3%
Mesa Laboratories logo
MLABClinical Genomics — Revenue
$12.18M+5.8%
BillionToOne, Inc. logo
BLLNClinical trial support and other services — Revenue
$1.54M+98.6%

Other financials

Income statement

See full
Revenue$678.2M-4.5%
Gross profit$139.2M+4.3%
Operating income$14.8M+104%
Net income-$13.2M+96.5%
EPS (diluted)-$0.14+96.6%

Balance sheet

See full
Cash & equivalents$168.6M+108%
Total debt$1.1B-10.0%
Total equity$524.2M-11.0%
Total assets$2.7B-4.2%

Cash flow

See full
Operating cash flow$28.9M
CapEx$9.0M+20.0%
Free cash flow-$25.0M+80.3%

Valuation

See full
Market cap$1.68B+182%
Enterprise value$2.63B+49.9%
P/S0.6×+0.4×

Profitability

See full
Gross margin19.3%-0.4pp
Operating margin-0.4%-0.2pp
Net margin-3.2%-1.5pp
FCF margin5.8%+2.0pp

Returns & leverage

See full
Return on equity-15.3%-7.0pp
Debt / equity2.1×0.0×
Current ratio-0.1×

Where this comes from

Reported directly by Fortrea Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Fortrea Holdings Inc.’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050597
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues$678.2$710.3$1,314.7$1,361.6
Less:
Pass through costs250.8276.3480.7516.2
Direct costs288.2298.7571.1592.8
Selling, general and administrative expenses94.3104.9183.4209.7
Depreciation5.05.010.210.0
Segment operating income39.925.469.332.9
Corporate costs not included in segment operating income7.821.719.339.5

Item 1. [Financial Statements (unaudited)](#i3eb220eb1643431ca98f46fb63169304_13)

FAQ

What is Fortrea Holdings Inc.'s clinical services segment — revenue?
Fortrea Holdings Inc. (FTRE) reported clinical services segment — revenue of $678.2M in Q2 2026.
How has Fortrea Holdings Inc.'s clinical services segment — revenue changed year-over-year?
Fortrea Holdings Inc.'s clinical services segment — revenue decreased by 4.5% year-over-year, from $710.3M to $678.2M.
What is the long-term trend for Fortrea Holdings Inc.'s clinical services segment — revenue?
Over 4 years (2021 to 2025), Fortrea Holdings Inc.'s clinical services segment — revenue has grown at a -0.4% compound annual growth rate (CAGR), from $2.76B to $2.72B.
What does clinical services segment — revenue mean?
Represents the total gross income generated by the clinical services business segment through the provision of clinical trial management and related research solutions. This metric reflects the scale of the segment's market activity and its ability to attract biopharma and medical device clients.

Ask your AI about Fortrea Holdings Inc.'s clinical services segment — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude